Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 55 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

24%

13 trials in Phase 3/4

Results Transparency

30%

7 of 23 completed with results

Key Signals

7 with results100% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (6)
Early P 1 (1)
P 1 (4)
P 2 (7)
P 3 (8)
P 4 (5)

Trial Status

Completed23
Unknown12
Recruiting10
Not Yet Recruiting4
Withdrawn3
Enrolling By Invitation2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (55)

Showing 20 of 20 trials
NCT04078568Phase 3CompletedPrimary

Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease

NCT07530640Not Yet RecruitingPrimary

Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities

NCT03750123Completed

Cardiovascular Status of Children 5 Years After Kawasaki Disease

NCT07491926Not Yet RecruitingPrimary

MASKd: a Study on Kawasaki Disease (KD) Complicated by Macrophage Activation Syndrome (MAS)

NCT04747847Early Phase 1CompletedPrimary

Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease

NCT07405658Not Yet RecruitingPrimary

Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease

NCT01917721Phase 2Active Not RecruitingPrimary

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT07291245Not ApplicableRecruitingPrimary

Kawasaki MATCH Trial

NCT06305611RecruitingPrimary

European and North Indian Cohort of KaWasaki dIsease

NCT06978439Phase 4RecruitingPrimary

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

NCT07086989Recruiting

Cardiovascular Risk in Children With Chronic Conditions Study

NCT04538495CompletedPrimary

Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease

NCT05643651Phase 4RecruitingPrimary

Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

NCT06993636RecruitingPrimary

Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years

NCT01793168Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

NCT04278404Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT06775457Not ApplicableRecruiting

Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)

NCT06697431Phase 4Not Yet RecruitingPrimary

Non Inferiority KawasakI Trial With Anakinra

NCT06641843Enrolling By InvitationPrimary

Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular Disease

NCT06641817Enrolling By InvitationPrimary

The Value of Cardiovascular Imaging in Kawasaki Disease

Scroll to load more

Research Network

Activity Timeline